Europe Gastrointestinal Drugs Market Summary
The Europe, Middle East and Africa Gastrointestinal Drugs market is projected to grow significantly over the next decade.
Key Market Trends & Highlights
Europe, Middle East and Africa Gastrointestinal Drugs Key Trends and Highlights
- The market valuation is expected to increase from 11.8 USD Billion in 2024 to 23.8 USD Billion by 2035.
- A compound annual growth rate (CAGR) of 6.58 percent is anticipated from 2025 to 2035.
- The growth trajectory suggests a robust demand for gastrointestinal drugs across the region.
- Growing adoption of advanced therapeutic options due to increasing prevalence of gastrointestinal disorders is a major market driver.
Market Size & Forecast
2024 Market Size | 11.8 (USD Billion) |
2035 Market Size | 23.8 (USD Billion) |
CAGR (2025-2035) | 6.58% |
Major Players
AstraZeneca Plc., Johnson & Johnson, Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Valeant Pharmaceuticals Inc., Sanofi Ltd., Abbott Laboratories, Allergan Plc, Bayer AG, Janssen Biotech Inc., AbbVie Inc., GlaxoSmithKline Plc., Boehringer Ingelheim GmbH